Top Left Logo
. Healthy People, Healthy Communities
Skip Navigation Links
For Health Professionals
Contact Us

Spacer Spacer Spacer Spacer
Index      Small Text Medium Text Large Text  

Nuclear and Molecular Medicine

Eastern Health’s Nuclear and Molecular Medicine facility houses Newfoundland and Labrador’s first positron emission tomography /computerized tomography (PET/CT) scanner.
The Nuclear and Molecular Medicine facility is state-of-the-art. It:
  • conveniently combines nuclear medicine services at one site;
  • provides adequate treatment space to run the Nuclear and Molecular Medicine Program; and
  • positions Eastern Health for future research opportunities.
Cyclotron Commissioning to Begin at Medical Imaging Facility  
Following approval by the Canadian Nuclear Safety Commission, Eastern Health has received a license to begin commissioning, or functional testing, of the cyclotron at the Medical Imaging Facility located at the Health Sciences Complex. The commissioning process will take place on Saturday, February 22 and Sunday, February 23 to eliminate any impact to patient appointments. During this time, visitors in the vicinity may notice signage and security near the building.  
Commissioning of the cyclotron involves turning on the machine and testing to ensure that the shielding and safety systems built into the facility, and the machine itself, operate as designed. Many safety features were built into the space that houses the cyclotron, such as extra thick concrete and lead walls, safety monitoring systems and security features.
Having a cyclotron on site will enable the production of medical isotopes on site, which are needed to operate the PET/CT scanner. In 2016, Eastern Health expanded medical imaging services to patients with the construction of a new medical imaging facility and the acquisition of a positron emission tomography /computerized tomography (PET/CT) to improve the diagnosis and treatment of certain illnesses, such as cancer. 
Eastern Health follows the safety guidelines issued by the Canadian Nuclear Safety Commission to ensure all individuals are kept safe during the commissioning process. There are two principal federal regulatory agencies involved – Canadian Nuclear Safety Commission (CSNC) and Health Canada. Eastern Health is also working closely with Health Canada to obtain approval of Eastern Health’s clinical trial application to produce and use FDG isotopes by Fall 2020. 


Updated Feb 20, 2020